PALISADE BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested
PALISADE BIO, INC. (PALI) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested of $200.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-20.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested · last filed 2026-03-20
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for the quarter ending 2023-12-31 was -$240.70M, a 481500.00% decline year-over-year.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for the quarter ending 2023-09-30 was $96.00M, a 38300.00% increase year-over-year.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for the quarter ending 2023-06-30 was $144.90M, a 48200.00% increase year-over-year.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for the quarter ending 2023-03-31 was $100.00K, a 75.00% decline year-over-year.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for fiscal 2025 was $200.00K, a 50.00% decline from fiscal 2024.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for fiscal 2024 was $400.00K, a 33.33% increase from fiscal 2023.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for fiscal 2023 was $300.00K, a 70.00% decline from fiscal 2022.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for fiscal 2022 was $1.00M, a 16.67% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested 12 month |
|---|---|---|---|---|
| 2025-12-31 | $200.00K 10-K · filed 2026-03-20 | |||
| 2024-12-31 | $400.00K 10-K · filed 2026-03-20 | |||
| 2023-12-31 | -$240.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$144.70M derived: sum of 2 quarters · filed 2025-03-24 | $200.00K derived: sum of 3 quarters · filed 2025-03-24 | $300.00K 10-K · filed 2025-03-24 |
| 2023-09-30 | $96.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $240.90M derived: sum of 2 quarters · filed 2023-11-09 | $241.00M 10-Q · filed 2023-11-09 | $241.05M derived: sum of 4 quarters · filed 2024-03-26 |
| 2023-06-30 | $144.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $145.00M 10-Q · filed 2023-08-10 | $145.05M derived: sum of 3 quarters · filed 2024-03-26 | $145.30M derived: sum of 4 quarters · filed 2024-03-26 |
| 2023-03-31 | $100.00K 10-Q · filed 2023-05-11 | $150.00K derived: sum of 2 quarters · filed 2024-03-26 | $400.00K derived: sum of 3 quarters · filed 2024-03-26 | $700.00K derived: sum of 4 quarters · filed 2024-03-26 |
| 2022-12-31 | $50.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $300.00K derived: sum of 2 quarters · filed 2024-03-26 | $600.00K derived: sum of 3 quarters · filed 2024-03-26 | $1.00M 10-K · filed 2024-03-26 |
| 2022-09-30 | $250.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $550.00K derived: sum of 2 quarters · filed 2022-11-14 | $950.00K 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $300.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $700.00K 10-Q · filed 2022-08-15 | ||
| 2022-03-31 | $400.00K 10-Q · filed 2022-05-13 | |||
| 2021-12-31 | $1.20M 10-K · filed 2023-03-22 | |||
| 2020-12-31 | $2.10M 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |